Q2 – ASCELIA

Skip to content

English
Svenska

ASCELIA
AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

About us
- Management
- Board of Directors
Diseases
- Liver metastases
- Gastric Cancer
Pipeline
- Mangoral
- Oncoral
Partnering
IR & Media
Governance
Career
Contact

2021
2020
2019
2018
2017

All All press releases Regulatory press releases Financial reports

Regulatory

2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 MALMÖ
Sweden
+46 735 179 118

Ascelia Pharma © 2019 | All Rights Reserved

Privacy policy Ascelia Pharma AB

Video

Cookies

We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy

Settings Accept all

Cookies

Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy

Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
Marketing
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.

Save Accept all